Tackling dementia globally: the Global Dementia Prevention Program (GloDePP) collaboration

Chan, Kit Yee; Asante, Kwaku Poku; Calia, Clara; Campbell, Harry; Danso, Samuel; Juvekar, Sanjay; Luz, Saturnino; Mohan, Devi; Muñiz‐Terrera, Graciela; Nitrini, Ricardo; Noroozıan, Maryam; Nulkar, Amit; Nyame, Solomon; Paralikar, Vasudeo; Rodríguez, Mario Alfredo Parra; Poon, Adrienne N; Reidpath, Daniel D.; Rudan, Igor; Stephan, Blossom C. M.; Su, TinTin; Wang, Huali; Watermeyer, Tam; Wilkinson, Heather; Yassuda, Mônica Sanches; Yu, Xin; Ritchie, Craig W.

doi:10.7189/jogh.09.020103

Cited by 8 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other examples include use of cognitive screening tools together with blood-based biomarkers to identify early-stage Alzheimer's, regular individualized assessment of cognitive function based on patient and family history, and ongoing close collaboration between primary care providers and Alzheimer's disease specialists [12]. Beyond the U.S., Chan et al 's overview in the Journal of Global Health reports on innovative programs to enhance all stages of dementia care, including early diagnosis, by reducing service fragmentation as well as raising knowledge and awareness of dementia among clinicians and community workers [8,32].…”

Section: Discussionmentioning

confidence: 99%

“…In other studies, a majority of patient participants were willing to undergo dementia screening, especially if they perceived benefits to screening or were in certain age groups [2]. Physicians are divided, with some worrying about the harms of dementia screening [6], while others argue that screening may improve the lives of people with dementia overall [7,8].…”

Section: Introductionmentioning

confidence: 99%

“…A body of international literature documents research and practice efforts aimed at supporting early dementia diagnosis [7][8][9] in developed and especially in low-and middle-income countries, where the majority of people with dementia live. The Global Dementia Prevention Program (GloDePP) prioritizes developing and piloting contextually appropriate digital and artificial intelligence tools for early detection of dementia and intervention.…”

Section: Introductionmentioning

confidence: 99%

“…Across countries, assessing neurophysiological signs of cognitive decline [10] and using mobile technologies (e.g. cell phone apps) for cognitive [11] evaluation are viewed as avenues to improving recognition of pre-symptomatic Alzheimer's disease and facilitating early diagnosis [8].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Patient and caregiver perspectives on a tool to increase recognition of undiagnosed dementia: a qualitative study

et al. 2021

View full text Add to dashboard Cite

Background Early detection of dementia may improve patient care and quality of life, yet up to half of people with dementia are undiagnosed. Electronic health record (EHR) data could be used to help identify individuals at risk of having undiagnosed dementia for outreach and assessment, but acceptability to people with dementia and caregivers is unknown. Methods We conducted five focus groups at Kaiser Permanente Washington (KPWA), an integrated healthcare system in Washington State, to explore people’s feelings about timing of dementia diagnosis, use of EHR-based tools to predict risk of undiagnosed dementia, and communication about risk. We recruited people enrolled in KPWA who had dementia or mild cognitive impairment, people enrolled in KPWA who had neither diagnosis, and caregivers (i.e., loved ones of people with dementia who assist with various tasks of daily life). People who were non-white or Hispanic were oversampled. Two team members analyzed transcripts using thematic coding. Results Forty people (63% women; 59% non-white or Hispanic) participated in the focus groups. Themes that arose included: perceived pros and cons of early dementia diagnosis; questions and concerns about a potential tool to assess risk of undiagnosed dementia; and preferences related to patient-provider conversations disclosing that a person was at high risk to have undiagnosed dementia. Participants supported early diagnosis, describing benefits such as time to adjust to the disease, plan, involve caregivers, and identify resources. They also acknowledged the possible psychosocial toll of receiving the diagnosis. Participants supported use of an EHR-based tool, but some people worried about accuracy and privacy. Participants emphasized that information about risk of undiagnosed dementia should be communicated thoughtfully by a trusted provider and that the conversation should include advice about prognosis, treatment options and other resources when a new dementia diagnosis was made. Conclusion People with dementia or mild cognitive impairment, people with neither diagnosis, and caregivers of people with dementia supported using EHR-based tools to help identify individuals at risk of having undiagnosed dementia. Such tools must be implemented carefully to address concerns and ensure that people living with dementia and their caregivers are adequately supported.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Patient and caregiver perspectives on a tool to increase recognition of undiagnosed dementia: a qualitative study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Alzheimer’s disease (AD) is one of the most impactful neurodegenerative diseases, affecting more than 50 million patients worldwide and costing healthcare systems $800 billion per year ( Chan et al, 2019 ). The common underlying pathology of this disease is the combination of deposition of amyloid plaques with tau neurofibrillary tangles (NFT) ( Braak and Braak, 1991 ), which is the driving cause of neurodegeneration and brain atrophy that leads to a progressive cognitive deterioration that affects multiple domains and eventually to a complete loss of function ( Jack et al, 2010 ).…”

Section: Introductionmentioning

confidence: 99%

Inter-Cohort Validation of SuStaIn Model for Alzheimer’s Disease

Archetti

Young

Oxtoby³

et al. 2021

Front. Big Data

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disorder which spans several years from preclinical manifestations to dementia. In recent years, interest in the application of machine learning (ML) algorithms to personalized medicine has grown considerably, and a major challenge that such models face is the transferability from the research settings to clinical practice. The objective of this work was to demonstrate the transferability of the Subtype and Stage Inference (SuStaIn) model from well-characterized research data set, employed as training set, to independent less-structured and heterogeneous test sets representative of the clinical setting. The training set was composed of MRI data of 1043 subjects from the Alzheimer’s disease Neuroimaging Initiative (ADNI), and the test set was composed of data from 767 subjects from OASIS, Pharma-Cog, and ViTA clinical datasets. Both sets included subjects covering the entire spectrum of AD, and for both sets volumes of relevant brain regions were derived from T1-3D MRI scans processed with Freesurfer v5.3 cross-sectional stream. In order to assess the predictive value of the model, subpopulations of subjects with stable mild cognitive impairment (MCI) and MCIs that progressed to AD dementia (pMCI) were identified in both sets. SuStaIn identified three disease subtypes, of which the most prevalent corresponded to the typical atrophy pattern of AD. The other SuStaIn subtypes exhibited similarities with the previously defined hippocampal sparing and limbic predominant atrophy patterns of AD. Subject subtyping proved to be consistent in time for all cohorts and the staging provided by the model was correlated with cognitive performance. Classification of subjects on the basis of a combination of SuStaIn subtype and stage, mini mental state examination and amyloid-β1-42 cerebrospinal fluid concentration was proven to predict conversion from MCI to AD dementia on par with other novel statistical algorithms, with ROC curves that were not statistically different for the training and test sets and with area under curve respectively equal to 0.77 and 0.76. This study proves the transferability of a SuStaIn model for AD from research data to less-structured clinical cohorts, and indicates transferability to the clinical setting.

show abstract

Exploring perceptions of travel-eligible individuals with dementia and hotel operators

Wen,

Zheng,

Jiang

et al. 2023

Anatolia

View full text Add to dashboard Cite

Tackling dementia globally: the Global Dementia Prevention Program (GloDePP) collaboration

Cited by 8 publications

References 18 publications

Patient and caregiver perspectives on a tool to increase recognition of undiagnosed dementia: a qualitative study

Patient and caregiver perspectives on a tool to increase recognition of undiagnosed dementia: a qualitative study

Inter-Cohort Validation of SuStaIn Model for Alzheimer’s Disease

Exploring perceptions of travel-eligible individuals with dementia and hotel operators

Contact Info

Product

Resources

About